Company: DNLI
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001714899-25-000105
Chunk: 97

Company: Denali Therapeutics Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 1
Chunk 97
---
2024, respectively1,778 1,768 Additional paid-in capital2,790,825 2,764,880 Accumulated other comprehensive income2,037 2,020 Accumulated deficit(1,671,954)(1,538,984)Total stockholders' equity1,122,686 1,229,684 Total liabilities and stockholders’ equity$1,271,343 $1,374,180 

See accompanying notes to unaudited condensed consolidated financial statements.

3

Table of Contents

Denali Therapeutics Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands, except share and per share amounts)

Three Months Ended March 31,20252024Operating expenses:Research and development$116,227 $107,016 General and administrative29,353 25,236 Total operating expenses145,580 132,252 Gain from divestiture of small molecule programs— 14,537 Loss from operations(145,580)(117,715)Interest and other income, net12,610 15,913 Net loss(132,970)(101,802)Other comprehensive income (loss):Net unrealized gain (loss) on marketable securities, net of tax17 (1,939)Comprehensive loss$(132,953)$(103,741)Net loss per share, basic and diluted$(0.78)$(0.68)Weighted average number of shares outstanding, basic and diluted171,222,030149,404,188

See accompanying notes to unaudited condensed consolidated financial statements.

4

Table of Contents

Denali Therapeutics Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

(In thousands, except share amounts)    

Common StockAdditional Paid-in CapitalAccumulated Other Comprehensive Income (Loss)Accumulated DeficitTotal Stockholders' EquitySharesAmountBalance at December 31, 2023138,385,498 $1,711 $2,144,811 $643 $(1,116,211)$1,030,954 Issuance of common stock and pre-funded warrants, net of issuance costs of $4803,244,689 32 499,221 — — 499,253 Issuances under equity incentive plans130,214 1 1,021 — — 1,022 Vesting of